Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

A. Hilary Calvert, David R. Newell, Lindsey Gumbrell et al. · Journal of Clinical Oncology · 1989 · 1.9K citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.

Barry Harris, Seng-Jaw Soong, Robert B. Diasio · PubMed · 1990 · 445 citations

Medicine, Pharmacokinetics, Pharmacology +17

Population study of dihydropyrimidine dehydrogenase in cancer patients.

M C Etienne, J.-L. Lagrange, O. Dassonville et al. · Journal of Clinical Oncology · 1994 · 432 citations

Medicine, Oncology, Pharmacology +15

Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.

Zhihong Lu, Ruiwen Zhang, Robert B. Diasio · PubMed · 1993 · 374 citations

Medicine, Oncology, Pharmacology +14

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

Kevin J. Scanlon, Edward M. Newman, Yuzhi Lu et al. · Proceedings of the National Academy of Sciences · 1986 · 369 citations

Medicine, Oncology, Pharmacology +16